Deoxycholic Acid and Risks of Cardiovascular Events, ESKD, and Mortality in CKD: The CRIC Study

[1]  M. Hu,et al.  Chronic Alcohol Consumption Increased Bile Acid Levels in Enterohepatic Circulation and Reduced Efficacy of Irinotecan. , 2020, Alcohol and alcoholism.

[2]  A. Go,et al.  Serum Calcification Propensity and Clinical Events in CKD. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[3]  M. Weir,et al.  Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease , 2019, Journal of the American Heart Association.

[4]  Douglas E Schaubel,et al.  US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Xianlin Han,et al.  Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome , 2018, Alzheimer's & Dementia.

[6]  Bangmao Wang,et al.  Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis. , 2018, Food & function.

[7]  Stephanie T. Lanza,et al.  Sensitivity and Specificity of Information Criteria , 2018, bioRxiv.

[8]  M. Metra,et al.  Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality , 2017, Circulation.

[9]  M. Miyazaki,et al.  Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  T. Hadden,et al.  Bile acid: a potential inducer of colon cancer stem cells , 2016, Stem Cell Research & Therapy.

[11]  F. He,et al.  Activation of FXR protects against renal fibrosis via suppressing Smad3 expression , 2016, Scientific Reports.

[12]  S. Kulling,et al.  Age-Related Changes of Plasma Bile Acid Concentrations in Healthy Adults—Results from the Cross-Sectional KarMeN Study , 2016, PloS one.

[13]  J. Meza,et al.  Urinary bile acids as biomarkers for liver diseases I. Stability of the baseline profile in healthy subjects. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  Ping Liu,et al.  Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. , 2015, Journal of proteome research.

[15]  Xunbo Jin,et al.  Mechanism underlying an elevated serum bile acid level in chronic renal failure patients , 2015, International Urology and Nephrology.

[16]  M. Miyazaki,et al.  Dual Activation of the Bile Acid Nuclear Receptor FXR and G-Protein-Coupled Receptor TGR5 Protects Mice against Atherosclerosis , 2014, PloS one.

[17]  D. Raj,et al.  The gut microbiome, kidney disease, and targeted interventions. , 2014, Journal of the American Society of Nephrology : JASN.

[18]  J. Montani,et al.  Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. , 2014, American journal of physiology. Renal physiology.

[19]  Carmen Cadarso-Suárez,et al.  smoothHR: An R Package for Pointwise Nonparametric Estimation of Hazard Ratio Curves of Continuous Predictors , 2013, Comput. Math. Methods Medicine.

[20]  D. Accili,et al.  Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids , 2013, Diabetes.

[21]  Masahira Hattori,et al.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome , 2013, Nature.

[22]  P. Edwards,et al.  Pleiotropic roles of bile acids in metabolism. , 2013, Cell metabolism.

[23]  G. Andersen,et al.  Chronic kidney disease alters intestinal microbial flora. , 2013, Kidney international.

[24]  F. Kuipers,et al.  Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism , 2010, Hepatology.

[25]  L. Adorini,et al.  Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model , 2010, Diabetes.

[26]  S. Fiorucci,et al.  FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats[S] , 2010, Journal of Lipid Research.

[27]  Chao-shu Tang,et al.  Endoplasmic reticulum stress-mediated apoptosis is activated in vascular calcification. , 2009, Biochemical and biophysical research communications.

[28]  A. Go,et al.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[29]  P. Stenvinkel,et al.  Vascular calcification in chronic kidney disease , 2009 .

[30]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[31]  G. London,et al.  Assessment and significance of arterial stiffness in patients with chronic kidney disease , 2008, Current opinion in nephrology and hypertension.

[32]  T. Jiang,et al.  Farnesoid X Receptor Modulates Renal Lipid Metabolism, Fibrosis, and Diabetic Nephropathy , 2007, Diabetes.

[33]  C M Payne,et al.  Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells. , 2007, Carcinogenesis.

[34]  T. Hishinuma,et al.  High sensitive analysis of rat serum bile acids by liquid chromatography/electrospray ionization tandem mass spectrometry. , 2006, Journal of pharmaceutical and biomedical analysis.

[35]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Hylemon,et al.  Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. , 2005, Journal of clinical gastroenterology.

[37]  A. Murray,et al.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.

[38]  M. Monte,et al.  Chronic Renal Failure-Induced Changes in Serum and Urine Bile Acid Profiles , 2002, Digestive Diseases and Sciences.

[39]  N. Chen,et al.  Vascular calcification in chronic kidney disease. , 2004, Seminars in nephrology.

[40]  A. Go,et al.  The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. , 2003, Journal of the American Society of Nephrology : JASN.

[41]  Qiuwei Xu,et al.  Bile acid binding to sevelamer HCl. , 2002, Kidney international.

[42]  E J Calabrese,et al.  Hormesis: U-shaped dose responses and their centrality in toxicology. , 2001, Trends in pharmacological sciences.

[43]  J. Skepper,et al.  Apoptosis Regulates Human Vascular Calcification In Vitro: Evidence for Initiation of Vascular Calcification by Apoptotic Bodies , 2000, Circulation research.

[44]  A. Catapano,et al.  Pharmacology of competitive inhibitors of HMG-CoA reductase. , 1995, Pharmacological research.

[45]  Z. Mareček,et al.  Bile composition in patients with chronic renal insufficiency. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  R. Hornung,et al.  Estimation of Average Concentration in the Presence of Nondetectable Values , 1990 .

[47]  D. Svendsgaard,et al.  U-shaped dose-response curves: their occurrence and implications for risk assessment. , 1990, Journal of toxicology and environmental health.

[48]  W. R. Bruce,et al.  Cellular toxicity of fecal water depends on diet. , 1987, The American journal of clinical nutrition.

[49]  S. Papson,et al.  “Model” , 1981 .

[50]  J. Tobin.  Estimation of Relationships for Limited Dependent Variables , 1958 .